Targeting eryptosis—alongside optimizing EPO and iron therapy—may represent a novel strategy to improve anemia management in NDD-CKD, though further longitudinal studies are needed to confirm causality and identify actionable molecular targets. Here, EPO is linked to chronic kidney disease.